Mounjaro® and hair loss

Three labels, three different answers

Mounjaro® contains tirzepatide, a once-weekly injection that acts on two gut hormone receptors, GIP and GLP-1. In the United States it is approved for type 2 diabetes in adults and children aged 10 and older, and to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk ^[1]. Its safety tables come from diabetes trials, where hair loss did not reach the threshold for the main table (at least 5% of people on Mounjaro® and more than on placebo) ^[1].

The only US mention is in section 6.2, which collects reports sent in after approval. That section warns that such reports come from a population of unknown size, so neither a rate nor a cause-and-effect link can be worked out from them ^[1]. The Medication Guide does not include hair loss among the most common side effects ^[2].

Europe tells a different story because there Mounjaro® is also licensed for weight management. Its product information pools 14 phase 3 studies with 15,169 adults and places hair loss in the “common” column, meaning between 1 in 100 and 1 in 10 people, with a footnote saying it mainly applies to people with overweight or obesity, with or without diabetes ^[3]. The patient leaflet repeats this as hair loss reported in people treated for weight management ^[3].

What studies of tirzepatide and its class add

The weight-reduction label for tirzepatide (Zepbound®) is the closest thing to a controlled number. It ties the hair loss it saw to weight reduction, reports it far more often in women than in men (7.1% versus 0.5% on treatment), and notes that no one on tirzepatide stopped the trials because of it ^[5]. The figure does not rise step by step with the dose ^[5].

A 2026 systematic review and meta-analysis of nine interventional studies, seven of them randomised, found hair loss about three times as likely with GLP-1 receptor agonists as with placebo (risk ratio 3.25), with an overall event rate of 3.9% in treated people ^[6]. The abstract reports the class as a whole and does not give a separate figure for tirzepatide.

A second 2026 meta-analysis combined cohort studies, pharmacovigilance analyses and case series covering more than a million patient exposures ^[7]. It found a 40% higher chance of non-scarring hair loss with GLP-1 medicines, driven by telogen effluvium (stress-related shedding) and pattern hair loss, while alopecia areata was not linked. Tirzepatide carried a reporting signal (reporting odds ratio 1.73). Reporting signals show that a pairing is reported more often than expected; they do not measure how many users are affected.

Why it may happen

What the labels support: the tirzepatide weight-reduction label connects hair loss with weight reduction, and the EU footnote points to the same group of people ^[3][5]. Mounjaro® itself lowers food intake and body weight, according to its pharmacology section ^[1].

What has been proposed but not measured in trials: the authors of the larger meta-analysis think shedding is mainly driven by low intake of nutrients during rapid weight loss ^[7]. That is a hypothesis built from observational data, not a finding from a controlled study.

General medical background: telogen effluvium happens when a stress on the body pushes many growing hairs into the resting phase at once. Cleveland Clinic lists restrictive diets low in protein and rapid weight loss among its triggers and notes that shedding often shows up two to three months after the trigger ^[9]. MedlinePlus gives crash diets short on protein as one cause of this type of shedding ^[8].

Other reasons hair thins

Shedding that starts during Mounjaro® treatment is not automatically caused by it. MedlinePlus lists heredity, physical or emotional stress, childbirth, major illness or surgery, thyroid disease, anemia, autoimmune conditions such as lupus, scalp infections, tight hairstyles and several medicines, including some blood pressure medicines, certain antidepressants and NSAIDs ^[8].

Alopecia areata, which causes round bald patches and can affect the beard or eyebrows, behaves differently from diffuse shedding, and the larger meta-analysis did not tie it to GLP-1 medicines ^[7][8]. A pattern that looks unusual is one reason MedlinePlus gives for seeing a clinician ^[8].

What tends to help

For shedding caused by a temporary stress, the sources are reassuring about the course. Cleveland Clinic says telogen effluvium usually lasts three to six months and that hair grows back, with most cases settling within six to eight months once the cause is dealt with ^[9]. MedlinePlus notes that hair loss linked to illness or medicine often needs no treatment and regrows when the cause has passed ^[8].

Cleveland Clinic advises avoiding extreme or restrictive diets and asking a clinician before adding supplements ^[9]. If eating enough is hard because appetite is very low, that is worth raising with your prescriber or a dietitian, since decreased appetite is one of Mounjaro®’s most common effects ^[1]. MedlinePlus mentions hairstyle changes or a covering as simple ways to manage the look while hair regrows ^[8].

Hair loss is not a reason the labels give for stopping Mounjaro®. Any change to treatment is a decision for your prescriber.

Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.